LDL lowering in peripheral arterial disease: Are there benefits beyond reducing cardiovascular morbidity and mortality?

Amy W. Pollak, Christopher M. Kramer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Peripheral arterial disease affecting the lower extremities is associated with increased mortality due to cardiovascular events and reduced functional capacity due to claudication. There is abundant evidence to support the role of lipid lowering with statins in preventing cardiovascular events in patients with peripheral arterial disease. Over the last 10 years, multiple studies have been designed to test the theory that LDL-C lowering with statins could result in improved exercise performance in patients with peripheral arterial disease. However, this remains an active area of investigation to better understand how the pleiotropic effects of statins could lead to enhanced functional capacity for patients with claudication. Furthermore, new insights into the complex pathophysiology of claudication may help us to understand the potential role of lipid-lowering therapy in alleviating exercise-induced symptoms.

Original languageEnglish (US)
Pages (from-to)141-149
Number of pages9
JournalClinical Lipidology
Volume7
Issue number2
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Peripheral Arterial Disease
Morbidity
Mortality
Exercise
Lipids
Lower Extremity
low density lipoprotein inhibitor
Therapeutics

Keywords

  • claudication
  • HMG-CoA reductase inhibitors
  • LDL-C
  • lipid lowering
  • peripheral arterial disease
  • statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

LDL lowering in peripheral arterial disease : Are there benefits beyond reducing cardiovascular morbidity and mortality? / Pollak, Amy W.; Kramer, Christopher M.

In: Clinical Lipidology, Vol. 7, No. 2, 04.2012, p. 141-149.

Research output: Contribution to journalArticle

@article{fa8d8d130a3a4255b05cff5b895e5642,
title = "LDL lowering in peripheral arterial disease: Are there benefits beyond reducing cardiovascular morbidity and mortality?",
abstract = "Peripheral arterial disease affecting the lower extremities is associated with increased mortality due to cardiovascular events and reduced functional capacity due to claudication. There is abundant evidence to support the role of lipid lowering with statins in preventing cardiovascular events in patients with peripheral arterial disease. Over the last 10 years, multiple studies have been designed to test the theory that LDL-C lowering with statins could result in improved exercise performance in patients with peripheral arterial disease. However, this remains an active area of investigation to better understand how the pleiotropic effects of statins could lead to enhanced functional capacity for patients with claudication. Furthermore, new insights into the complex pathophysiology of claudication may help us to understand the potential role of lipid-lowering therapy in alleviating exercise-induced symptoms.",
keywords = "claudication, HMG-CoA reductase inhibitors, LDL-C, lipid lowering, peripheral arterial disease, statin",
author = "Pollak, {Amy W.} and Kramer, {Christopher M.}",
year = "2012",
month = "4",
doi = "10.2217/clp.12.6",
language = "English (US)",
volume = "7",
pages = "141--149",
journal = "Future Lipidology",
issn = "1746-0875",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - LDL lowering in peripheral arterial disease

T2 - Are there benefits beyond reducing cardiovascular morbidity and mortality?

AU - Pollak, Amy W.

AU - Kramer, Christopher M.

PY - 2012/4

Y1 - 2012/4

N2 - Peripheral arterial disease affecting the lower extremities is associated with increased mortality due to cardiovascular events and reduced functional capacity due to claudication. There is abundant evidence to support the role of lipid lowering with statins in preventing cardiovascular events in patients with peripheral arterial disease. Over the last 10 years, multiple studies have been designed to test the theory that LDL-C lowering with statins could result in improved exercise performance in patients with peripheral arterial disease. However, this remains an active area of investigation to better understand how the pleiotropic effects of statins could lead to enhanced functional capacity for patients with claudication. Furthermore, new insights into the complex pathophysiology of claudication may help us to understand the potential role of lipid-lowering therapy in alleviating exercise-induced symptoms.

AB - Peripheral arterial disease affecting the lower extremities is associated with increased mortality due to cardiovascular events and reduced functional capacity due to claudication. There is abundant evidence to support the role of lipid lowering with statins in preventing cardiovascular events in patients with peripheral arterial disease. Over the last 10 years, multiple studies have been designed to test the theory that LDL-C lowering with statins could result in improved exercise performance in patients with peripheral arterial disease. However, this remains an active area of investigation to better understand how the pleiotropic effects of statins could lead to enhanced functional capacity for patients with claudication. Furthermore, new insights into the complex pathophysiology of claudication may help us to understand the potential role of lipid-lowering therapy in alleviating exercise-induced symptoms.

KW - claudication

KW - HMG-CoA reductase inhibitors

KW - LDL-C

KW - lipid lowering

KW - peripheral arterial disease

KW - statin

UR - http://www.scopus.com/inward/record.url?scp=84860112755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860112755&partnerID=8YFLogxK

U2 - 10.2217/clp.12.6

DO - 10.2217/clp.12.6

M3 - Article

AN - SCOPUS:84860112755

VL - 7

SP - 141

EP - 149

JO - Future Lipidology

JF - Future Lipidology

SN - 1746-0875

IS - 2

ER -